![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1754023
HPV °Ë»ç ¹× PAP °Ë»ç ½ÃÀå º¸°í¼ : °Ë»ç À¯Çü, Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)HPV Testing and PAP Test Market Report by Test Type, Product, Application, End User, and Region 2025-2033 |
¼¼°è HPV °Ë»ç ¹× PAP °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â 44¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀåÀÌ 70¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.96%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV)´Â ÀڱðæºÎ, ±¸°ÀεÎ, À½°æ, À½°æ¿ÜÀ½ºÎ¿¡ ¾ÏÀ» À¯¹ßÇÏ´Â ¼ºº´(STI)À¸·Î, HPV ¹× ÀڱðæºÎ ¼¼Æ÷Áø °Ë»ç(PAP) °Ë»ç µî ´Ù¾çÇÑ °Ë»ç¿Í ½Ã¼úÀ» ÅëÇØ °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â °ËüÀÇ Çö¹Ì°æ °üÂû°ú ÀڱðæºÎ¾Ï, µÎ°æºÎ¾Ï °ËÁøÀ¸·Î ÀÌ·ç¾îÁý´Ï´Ù. ÀÌ Áß HPV °Ë»ç´Â »ý½Ä±â »ç¸¶±ÍÀÇ ¹ß´Þ¿¡ ¼±ÇàÇÏ´Â ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½ºÀÇ Á¸À縦 Æò°¡Çϱâ À§ÇØ ½ÃÇàµÇ¸ç, PAP °Ë»ç´Â ¼¼Æ÷ÀÇ º¯È³ª ÀڱðæºÎÀÇ ÀÌ»ó ¼¼Æ÷ÀÇ Á¸À縦 ÆÇ´ÜÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù.
À¯µÎÁ¾ ¹ÙÀÌ·¯½ºÀÇ Á¸Àç·Î ÀÎÇØ ÀڱðæºÎ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ¼ºÀÎÃþ¿¡¼ ÀڱðæºÎ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±â¼úÀûÀ¸·Î Áøº¸µÈ »õ·Î¿î ºñ¿ë È¿À²ÀûÀÎ HPV ¹× PAP ½ºÅ©¸®´×ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÁÖ·Î ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ¿Í ÇÔ²² HPV °¨¿° ¾ÏÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á ¹ÝÀÀ ¸ð´ÏÅ͸µÀ» À§ÇÑ ±â°è Áö¿ø Ç÷Àå ¹× ¹«¼¼Æ÷ µ¥¿Á½Ã¸®º¸ÇÙ»ê(DNA) ½ºÅ©¸®´×ÀÇ µµÀÔÀº ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ °©ÀÛ½º·¯¿î ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ÁÖ¿ä ¾÷üµéÀÇ Áö¼ÓÀûÀÎ ÀÓ»ó½ÃÇè, °³¹ß ¹× Á¦Ç° Ãâ½Ã(¿¹: »ç¿ëÇϱ⠽¬¿î °¡Á¤¿ë HPV ½ºÅ©¸®´× °Ë»ç µî)°¡ ½ÃÀå¿¡¼ÀÇ °æÀï ¿ìÀ§¸¦ °¡Á®¿À°í ÀÖ´Â °Íµµ ¼ºÀå µ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ºÐ¾ßÀÇ ±Þ¼ÓÇÑ ¼ºÀå°ú ÀڱðæºÎ¾ÏÀÇ ¿øÀΰú HPV °Ë»ç ¹× PAP °Ë»çÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ Á¤ºÎ ±â°ü ¹× ºñÁ¤ºÎ±â±¸(NGO)°¡ ½ÃÇàÇϰí ÀÖ´Â ¿©·¯ °¡Áö ±àÁ¤ÀûÀÎ ³ë·Â°ú °°Àº ´Ù¸¥ ¿äÀε鵵 ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù.
The global HPV testing and PAP test market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor. This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.